Research programme: KRAS mutant inhibitors - Singh Biotechnology

Drug Profile

Research programme: KRAS mutant inhibitors - Singh Biotechnology

Alternative Names: Inhibitors of mutated KRAS - Singh Biotechnology; SBT 102 - Singh Biotechnology

Latest Information Update: 05 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Singh Biotechnology
  • Class Antineoplastics
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 17 Oct 2017 Singh Biotechnology plans a phase I trial for Cancer in 2018 (Singh Biotechnology pipeline, October 2017)
  • 04 Aug 2016 Singh Biotechnology has patent protection for KRAS mutant inhibitors (Singh Biotechnology website, August 2016)
  • 01 Dec 2015 Early research is underway in Cancer in USA (Singh Biotechnology website, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top